Rethinking therapeutic decisions for hepatitis B infection in Syria: insights into molecular monitoring
Introduction: Hepatitis B virus patients are usually treated in Syria with alpha interferon and nucleos(t)ide analogues. Genotypic viral factors causing inadequate response or relapse following initial response are not routinely investigated. This study aimed to explore and discuss local therapeutic...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2012-10-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/2596 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850036230726615040 |
|---|---|
| author | Wafa Habbal Fawza Monem |
| author_facet | Wafa Habbal Fawza Monem |
| author_sort | Wafa Habbal |
| collection | DOAJ |
| description | Introduction: Hepatitis B virus patients are usually treated in Syria with alpha interferon and nucleos(t)ide analogues. Genotypic viral factors causing inadequate response or relapse following initial response are not routinely investigated. This study aimed to explore and discuss local therapeutic decisions from a molecular perspective.
Methodology: Fifty patients with hepatitis B from Syria were tested for HBV genotyping and drug-resistance mutations by DNA sequencing.
Results: All patients had genotype D, which is characterized by relatively low response to interferon-based therapy. Drug-resistant viral mutant variants were detected in one fifth of the enrolled patients, and distributed similarly in both nucleos(t)ide analogues-naïve and -treated patients. However, nucleos(t)ide analogues-based therapy was associated with the existence of more mutations and hence increased resistance.
Conclusions: Investigating HBV genotypes and drug-resistance mutations to support treatment decisions is critically needed for efficient therapy and patients’ survival.
|
| format | Article |
| id | doaj-art-8c582674257243e598355d79c856e1cd |
| institution | DOAJ |
| issn | 1972-2680 |
| language | English |
| publishDate | 2012-10-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-8c582674257243e598355d79c856e1cd2025-08-20T02:57:14ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802012-10-0161010.3855/jidc.2596Rethinking therapeutic decisions for hepatitis B infection in Syria: insights into molecular monitoringWafa Habbal0Fawza Monem1Al-Assad Hospital, Damascus University, Damascus, SyriaAl-Assad Hospital, Damascus University, Damascus, SyriaIntroduction: Hepatitis B virus patients are usually treated in Syria with alpha interferon and nucleos(t)ide analogues. Genotypic viral factors causing inadequate response or relapse following initial response are not routinely investigated. This study aimed to explore and discuss local therapeutic decisions from a molecular perspective. Methodology: Fifty patients with hepatitis B from Syria were tested for HBV genotyping and drug-resistance mutations by DNA sequencing. Results: All patients had genotype D, which is characterized by relatively low response to interferon-based therapy. Drug-resistant viral mutant variants were detected in one fifth of the enrolled patients, and distributed similarly in both nucleos(t)ide analogues-naïve and -treated patients. However, nucleos(t)ide analogues-based therapy was associated with the existence of more mutations and hence increased resistance. Conclusions: Investigating HBV genotypes and drug-resistance mutations to support treatment decisions is critically needed for efficient therapy and patients’ survival. https://jidc.org/index.php/journal/article/view/2596hepatitis B virusSyriatherapeutic decisionsviral genotypemutant variantsdrug resistance |
| spellingShingle | Wafa Habbal Fawza Monem Rethinking therapeutic decisions for hepatitis B infection in Syria: insights into molecular monitoring Journal of Infection in Developing Countries hepatitis B virus Syria therapeutic decisions viral genotype mutant variants drug resistance |
| title | Rethinking therapeutic decisions for hepatitis B infection in Syria: insights into molecular monitoring |
| title_full | Rethinking therapeutic decisions for hepatitis B infection in Syria: insights into molecular monitoring |
| title_fullStr | Rethinking therapeutic decisions for hepatitis B infection in Syria: insights into molecular monitoring |
| title_full_unstemmed | Rethinking therapeutic decisions for hepatitis B infection in Syria: insights into molecular monitoring |
| title_short | Rethinking therapeutic decisions for hepatitis B infection in Syria: insights into molecular monitoring |
| title_sort | rethinking therapeutic decisions for hepatitis b infection in syria insights into molecular monitoring |
| topic | hepatitis B virus Syria therapeutic decisions viral genotype mutant variants drug resistance |
| url | https://jidc.org/index.php/journal/article/view/2596 |
| work_keys_str_mv | AT wafahabbal rethinkingtherapeuticdecisionsforhepatitisbinfectioninsyriainsightsintomolecularmonitoring AT fawzamonem rethinkingtherapeuticdecisionsforhepatitisbinfectioninsyriainsightsintomolecularmonitoring |